Eleva Receives Orphan Drug Designation in Europe for Proprietary Factor H Therapy in C3 Glomerulopathy (C3G)
July 3, 2024 – BioManufacturing, Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical – C3 Glomerulopathy, Eleva Biologics, Orphan Drug Designation, biologics development
3 July 2024 — Freiburg Im Breisgau, Germany — Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today that the European Commission (EC) has granted the Orphan Drug Designation (ODD) for Factor H (CPV-104), the company’s recombinant version of human complement Factor H, to treat C3 Glomerulopathy (C3G). Eleva is preparing a first clinical study in C3G and expects to commence dosing patients in H1 2025.
“Today’s news marks an important milestone for Eleva’s R&D and regulatory teams, as the ODD adds significant value to the Factor H (CPV-104) programme. The positive opinion by the EMA is also a clear validation for the comprehensive preclinical data sets we have generated for our programme,” commented Andreas Schaaf PhD, chief scientific officer of Eleva. “Overall, Factor H (CPV-104) continues to progress steadily towards clinical studies and is emerging rapidly as a potential first-in-class solution for C3G and potentially other complement-related disorders.”
The ODD in the EU was granted by the EC based on a positive opinion issued previously by the EMA Committee for Orphan Medicinal Products (COMP). The programme is focused on the development of drugs that have shown the potential to provide significant benefit to patients suffering from rare, life-threatening diseases. Following market approval, the ODS designation would provide Eleva with ten years of market exclusivity and provides special incentives, including eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees.
C3G represents a rare renal disease caused by the dysregulation of the complement system, a central part of the body’s immune defense. Naturally occurring complement regulators such as Factor H can provide a pro-resolutive option for restoring the balance of the complement system. Preclinical data sets recently published in Frontiers in Immunology point towards Factor H (CPV-104)’s ability to act as a functional analogue of human Factor H, support normalisation of serum C3 levels and the rapid degradation of C3 deposits in the kidney.
About Eleva
Eleva is a clinical-stage biopharmaceutical company unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform. The company’s proprietary drug development activities currently focus on complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant version of human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. The company’s aGal (RPV-001) programme to treat Fabry disease has completed a phase 1b clinical study with promising results. All programmes are sourced from Eleva’s transformative moss-based expression system, which allows lab to GMP-scale manufacturing of challenging proteins with previously untapped therapeutic potential. Visit: https://elevabiologics.com.
